Open an account

Pacific Biosciences of California

PACB · NASDAQ

$1.96+$0.12 (+6.52%)TodayMarket closed ·
Prev close $1.84

About PACB

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 485 full-time employees. The company went IPO on 2010-10-27. The firm designs, develops, and manufactures sequencing solutions. Its products and technology include HiFi long-read sequencing technology, which addresses a set of applications including human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology, and other applications. Its sequencing technology supports oncology research by enabling analysis of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), providing researchers with insight into cancer biology. The company focuses on creating sequencing systems to provide customers with a view of genomes, transcriptomes, and epigenomes. Its customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.

Employees
485
Headquarters
Menlo Park, California
Listed
Oct 27, 2010
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
pacb.com

PACB key statistics

Market cap
609.23M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
19.73M
Volume
10.36M
Open price
$1.80
High today
$2.06
Low today
$1.76
52 Week high
$3.44
52 Week low
$1.07

Pacific Biosciences of California (PACB) at a glance

As of Oct 20, 2026, Pacific Biosciences of California (PACB) shares are priced at $1.96, giving the company a market cap of 609.23M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.76 and $2.06. The current price is 11.4% above the day's low and 4.9% below its high.

Volume so far is 10.36M shares, below the average of 19.73M shares a day.

Over the past year Pacific Biosciences of California has ranged from $1.07 to $3.44, and now sits 38% of the way up that range.

Pacific Biosciences of California met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.14 per share against an estimate of -$0.1297.

The average analyst price target is $2.20, 12.3% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

25%of 4 analyst ratings say Buy
  • Buy25.0%
  • Hold50.0%
  • Sell25.0%
Price target · 9 analystsAvg $2.20
Low
$1.26
Now
$1.96
High
$3.15

PACB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 14.5% on average.

  1. Q3 FY24: reported -$0.22 per share against an estimate of -$0.229
  2. Q4 FY24: reported -$0.49 per share against an estimate of -$0.2095
  3. Q1 FY25: reported -$1.44 per share against an estimate of -$0.1928
  4. Q2 FY25: reported -$0.14 per share against an estimate of -$0.1734
  5. Q3 FY25: reported -$0.13 per share against an estimate of -$0.155
  6. Q4 FY25: reported -$0.12 per share against an estimate of -$0.1505
  7. Q1 FY26: reported -$0.12 per share against an estimate of -$0.1375
  8. Q2 FY26: reported -$0.14 per share against an estimate of -$0.1297

PACB news

  • Shivdeep Dhaliwal

    Cathie Wood Sells Robinhood Stock, Doubles Down On This George Soros-Backed AI Stock

  • Press releaseBusiness Wire

    Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology

  • Uncovering Potential: Pacific Biosciences's Earnings Preview

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • Shivdeep Dhaliwal

    Cathie Wood Just Dumped $7.4 Million Worth Of Palantir And AMD Shares — Here's What Ark Is Buying Instead

  • Avi Kapoor

    Applied Materials, GameStop And Other Big Stocks Moving Lower In Friday's Pre-Market Session

  • The Analyst Verdict: Pacific Biosciences In The Eyes Of 4 Experts

Similar companies

Companies in the same industry as Pacific Biosciences of California

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.